Double-Blind, Placebo-Controlled Investigation of Amantadine for Weight Loss in Subjects Who Gained Weight With Olanzapine
Abstract
OBJECTIVE: This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine. METHOD: Twenty-one adults who had gained at least 5 lb with olanzapine were randomly assigned to receive amantadine (N=12) or placebo (N=9) in addition to olanzapine. The length of time taking olanzapine ranged from 1 to 44 months. Body mass index, psychiatric status, and fasting blood levels were assessed at baseline and 12 weeks. RESULTS: Significantly fewer subjects taking amantadine gained weight, with a mean change in body mass index of -0.07 kg/m2 for the amantadine group and 1.24 kg/m2 for the placebo group. This effect remained significant when the authors controlled for baseline body mass index and length of olanzapine treatment. No changes in fasting glucose, insulin, leptin, prolactin, and lipid levels were seen. Positive and Negative Syndrome Scale scores remained stable. CONCLUSIONS: Amantadine induced weight stabilization in subjects taking olanzapine and was well tolerated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients, implementation and sustainability of regular exercise commitment remains problematic due to poor motivation, side effects of medications, social barriers, and symptoms.
“In patients implementation and sustainability of regular exercise commitment remains problematic due to poor motivation, 73 side effects of medications, 74,75 social barriers, 76 and symptoms. 73”
From Physical exercise keeps the brain connected: biking increases white matter integrity in patients with schizophrenia and healthy controls. (2015) · cites this paper as [74]
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382 · see citing works
Hypothalamic dopamine and serotonin in the regulation of food intake
Meguid, M. M., Fetissov, S. O., Varma, M., Sato, T., Zhang, L., Laviano, A., & Fanelli, F. R. (2000) · Nutrition · doi:10.1016/s0899-9007(00)00449-4 · Cited by 423 · see citing works
Body weight gain induced by antipsychotic drugs: mechanisms and management
Baptista, T. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb10908.x · Cited by 304 · see citing works
Pharmacologic activation of limbic structures and neuroimaging studies of emotions.
Beasley, C. M., Tollefson, G. D., & Tran, P. V. (1997) · PubMed · Cited by 197 · see citing works
Effect of amantadine on weight gain during olanzapine treatment
Floris, M., Lejeune, J., & Deberdt, W. G. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00072-4 · Cited by 85 · see citing works
Amantadine in the Treatment of Neuroendocrine Side Effects of Neuroleptics
Correa, N., Opler, L. A., Kay, S. R., et al. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198704000-00008 · Cited by 81 · see citing works
Frankle, W., Gil, R. B., Hackett, E., Mawlawi, O., Zea-Ponce, Y., Zhu, Z., Kochan, L., Cangiano, C., Slifstein, M., Gorman, J., et al. (2003) · Psychopharmacology · doi:10.1007/s00213-004-1852-4 · Cited by 50 · see citing works
Amantadine Treatment of Psychotropic-Induced Weight Gain in Children and Adolescents: Case Series
Gracious, B., Krysiak, T. E., & Youngstrom, E. A. (2002) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454602760386941 · Cited by 34 · see citing works
Baptista, T., López, M., Teneud, L., et al. (1997) · Pharmacopsychiatry · doi:10.1055/s-2007-979482 · Cited by 32 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cooper, S. J., Reynolds, G. P., order):, W. E. C.-A. (. A., Barnes, T., England, E., Haddad, P., Heald, A., Holt, R., Lingford-Hughes, A., Osborn, D., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645254 · Cited by 292 · see citing works
Svatkova, A., Mandl, R. C. W., Scheewe, T. W., Cahn, W., Kahn, R. S., & Hulshoff Pol, H. E. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv033 · Cited by 120 · see citing works
Bupropion Treatment of Olanzapine-Associated Weight Gain: An Open-Label, Prospective Trial
Gadde, K. M., Zhang, W., & Foust, M. S. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000227354.54074.5d · Cited by 24 · see citing works
- Authors
- Graham, K. A., Gu, H., Lieberman, J. A., Harp, J. B., & Perkins, D. O.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- American Journal of Psychiatry
- Published
- 2005-09-01
- Volume
- 162
- Issue
- 9
- Pages
- 1744-1746
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2040340453
- Cited by
- 92
- References
- 10
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 5 · 2012: 10
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56350, P30DK056350)
- National Center for Research Resources (RR00046, M01RR000046)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- amantadine, olanzapine, weight gain, antipsychotic-induced weight gain, body mass index, psychiatric patients, antipsychotic adverse effects, drug tolerability
- MeSH terms
- Olanzapine, Amantadine, Benzodiazepines, Double-Blind Method, Female, Humans, Male, Obesity, Placebos, Schizophrenia, Antipsychotic Agents, Dopamine Agents, Weight Loss, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
